Cargando…

非小细胞肺癌切除组织中常用免疫组织化学指标尚不能预测远期生存

BACKGROUND AND OBJECTIVE: It has been drawn much attention to identify the molecular markers by immunohistochemistry (IHC) for evaluating the prognosis of non-small cell lung cancer (NSCLC) following resection. The aim of this study is to retrospectively associate ever tested IHC markers and prognos...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5999823/
https://www.ncbi.nlm.nih.gov/pubmed/27009819
http://dx.doi.org/10.3779/j.issn.1009-3419.2016.03.05
_version_ 1783331521629782016
collection PubMed
description BACKGROUND AND OBJECTIVE: It has been drawn much attention to identify the molecular markers by immunohistochemistry (IHC) for evaluating the prognosis of non-small cell lung cancer (NSCLC) following resection. The aim of this study is to retrospectively associate ever tested IHC markers and prognosis of NSCLC after resection. METHODS: A total of 722 NSCLC patients underwent surgery by single surgeon team from 2008 to 2013. Twelve molecular markers had been examined by IHC and the staining signals was re-scored with unified standard. Survival analysis by univariate and multivariate was carried out to assess the significance of these markers in prognosis of NSCLC in our prospective database with strict follow-up. RESULTS: The following twelve IHC markers had been tested between 2008 and 2013, including platelet-derived growth factor receptor (PDGFR)(n=124), excision repair cross complementing 1 (ERCC1)(n=124), epithelial growth factor receptor (EGFR)(n=131), vascular endothelial growth factor receptor 3 (VEGFR3)(n=142), NM23 (n=129), MRP (n=109), P170 (n=104), TS (n=143), Tubulin (n=133), ribonucleotide reductase M1 (RRM1)(n=131), ribonucleotide reductase M1 (COX2)(n=138), and TOPII (n=127). Only VEGFR3 expression was correlated with prognosis of the patients by univariate analysis, with 5-yrs survival rate being 77.6% and 65.0% (positive vs. negative) respectively (P=0.042). However, VEGFR3 was not an independent prognostic factor for this series of NSCLC patients in multivariate analysis. CONCLUSION: These twelve IHC markers could not predict prognosis of NSCLC patients after surgery in our series.
format Online
Article
Text
id pubmed-5999823
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher 中国肺癌杂志编辑部
record_format MEDLINE/PubMed
spelling pubmed-59998232018-07-06 非小细胞肺癌切除组织中常用免疫组织化学指标尚不能预测远期生存 Zhongguo Fei Ai Za Zhi 临床研究 BACKGROUND AND OBJECTIVE: It has been drawn much attention to identify the molecular markers by immunohistochemistry (IHC) for evaluating the prognosis of non-small cell lung cancer (NSCLC) following resection. The aim of this study is to retrospectively associate ever tested IHC markers and prognosis of NSCLC after resection. METHODS: A total of 722 NSCLC patients underwent surgery by single surgeon team from 2008 to 2013. Twelve molecular markers had been examined by IHC and the staining signals was re-scored with unified standard. Survival analysis by univariate and multivariate was carried out to assess the significance of these markers in prognosis of NSCLC in our prospective database with strict follow-up. RESULTS: The following twelve IHC markers had been tested between 2008 and 2013, including platelet-derived growth factor receptor (PDGFR)(n=124), excision repair cross complementing 1 (ERCC1)(n=124), epithelial growth factor receptor (EGFR)(n=131), vascular endothelial growth factor receptor 3 (VEGFR3)(n=142), NM23 (n=129), MRP (n=109), P170 (n=104), TS (n=143), Tubulin (n=133), ribonucleotide reductase M1 (RRM1)(n=131), ribonucleotide reductase M1 (COX2)(n=138), and TOPII (n=127). Only VEGFR3 expression was correlated with prognosis of the patients by univariate analysis, with 5-yrs survival rate being 77.6% and 65.0% (positive vs. negative) respectively (P=0.042). However, VEGFR3 was not an independent prognostic factor for this series of NSCLC patients in multivariate analysis. CONCLUSION: These twelve IHC markers could not predict prognosis of NSCLC patients after surgery in our series. 中国肺癌杂志编辑部 2016-03-20 /pmc/articles/PMC5999823/ /pubmed/27009819 http://dx.doi.org/10.3779/j.issn.1009-3419.2016.03.05 Text en 版权所有©《中国肺癌杂志》编辑部2016 https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/
spellingShingle 临床研究
非小细胞肺癌切除组织中常用免疫组织化学指标尚不能预测远期生存
title 非小细胞肺癌切除组织中常用免疫组织化学指标尚不能预测远期生存
title_full 非小细胞肺癌切除组织中常用免疫组织化学指标尚不能预测远期生存
title_fullStr 非小细胞肺癌切除组织中常用免疫组织化学指标尚不能预测远期生存
title_full_unstemmed 非小细胞肺癌切除组织中常用免疫组织化学指标尚不能预测远期生存
title_short 非小细胞肺癌切除组织中常用免疫组织化学指标尚不能预测远期生存
title_sort 非小细胞肺癌切除组织中常用免疫组织化学指标尚不能预测远期生存
topic 临床研究
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5999823/
https://www.ncbi.nlm.nih.gov/pubmed/27009819
http://dx.doi.org/10.3779/j.issn.1009-3419.2016.03.05
work_keys_str_mv AT fēixiǎoxìbāofèiáiqièchúzǔzhīzhōngchángyòngmiǎnyìzǔzhīhuàxuézhǐbiāoshàngbùnéngyùcèyuǎnqīshēngcún
AT fēixiǎoxìbāofèiáiqièchúzǔzhīzhōngchángyòngmiǎnyìzǔzhīhuàxuézhǐbiāoshàngbùnéngyùcèyuǎnqīshēngcún
AT fēixiǎoxìbāofèiáiqièchúzǔzhīzhōngchángyòngmiǎnyìzǔzhīhuàxuézhǐbiāoshàngbùnéngyùcèyuǎnqīshēngcún
AT fēixiǎoxìbāofèiáiqièchúzǔzhīzhōngchángyòngmiǎnyìzǔzhīhuàxuézhǐbiāoshàngbùnéngyùcèyuǎnqīshēngcún
AT fēixiǎoxìbāofèiáiqièchúzǔzhīzhōngchángyòngmiǎnyìzǔzhīhuàxuézhǐbiāoshàngbùnéngyùcèyuǎnqīshēngcún
AT fēixiǎoxìbāofèiáiqièchúzǔzhīzhōngchángyòngmiǎnyìzǔzhīhuàxuézhǐbiāoshàngbùnéngyùcèyuǎnqīshēngcún
AT fēixiǎoxìbāofèiáiqièchúzǔzhīzhōngchángyòngmiǎnyìzǔzhīhuàxuézhǐbiāoshàngbùnéngyùcèyuǎnqīshēngcún